Medis has been developing software solutions to support the healthcare professionals in their CT, MR, X-Ray and Ultrasound procedures for over 30 years. To learn more about ACIST, visit About Medis Medis Medical Imaging develops, markets and supports high quality and powerful software with innovative post-processing solutions for cardiovascular imaging. Headquartered in Eden Prairie, Minn., ACIST has worldwide presence with over 300 direct employees and facilities in Silicon Valley, Heerlen, and Tokyo. As part of the Bracco Group, ACIST benefits from the resources of a multinational conglomerate with broad expertise in cath lab technology and a dedication to continuous advancement. Through these products, ACIST is demonstrating its commitment to bringing unique and innovative technologies that simplify cardiovascular procedures and empower clinicians to treat patients with superior care. The company also includes BRACCO INJENEERING, which provides injection technology solutions for state-of-the-art radiology centers. It is also a global market leader in advanced contrast imaging systems for cardiovascular angiography and radiology imaging. is a pioneering interventional and diagnostic technology company with a portfolio of advanced products, including the world’s first Rapid Exchange FFR and High Definition IVUS systems. Introducing QFR® in the USA is in line with the aspiration of Medis to establish QFR® as the world’s leading technology in angio-based functional assessments,” stated Hans Brons, CEO of Medis.Ībout ACIST ACIST Medical Systems, Inc. “Collaborating with ACIST expands our global reach with a proven commercial partner in the USA, helping Medis bring value-based, clinically proven imaging innovation to more clinicians and patients.
Medis medical imaging systems professional#
QFR provides the healthcare professional with more extensive and quantitative physiologic imaging results to support the patient’s diagnosis and better inform the patient’s treatment. Unlike traditional invasive assessments, including FFR and iFR, the QFR analysis output is co-registered with the angiogram and automatically identifies and prioritizes any functionally significant coronary obstructions. The QFR analysis is performed during the interventional procedure and can streamline workflow in the cath lab while driving economic value. While still in early clinical use, QFR and other angio-derived FFR systems will become a dominant method in the coming years by improving the patient experience and simplifying PCI decision-making.” Like other angiographically derived FFR systems, QFR will let the angiographer see the physiologic impact of the stenoses within a vessel of interest and make an informed decision on whether to stent or not without the need of a pressure wire or adenosine.
QFR® also improves the patient experience with fast procedure times, no invasive pressure wire, and no required adenosine administration.Īccording to Morton Kern MD, Chief of Cardiology and interventional cardiologist at the VA Long Beach Healthcare System, California, “QFR represents a significant advance for assessment of coronary artery disease in the cath lab.
The novel QFR® approach applies advanced mathematical modeling to accurately and effectively measure the physiologic and anatomical extent of a patient’s coronary artery disease. Medis’ QFR® is a proprietary solution delivering image-based functional assessment of coronary obstructions from standard coronary angiograms. This partnership solidifies ACIST’s position as the preferred physiology partner of choice with the ability to offer both invasive and non-invasive approaches to support the clinical utility that physiology provides,” said Brad Fox, President and CEO, ACIST Medical Systems, Inc. “This strategic collaboration expands our portfolio and enables ACIST to better support the evolving needs of our customer.